Tokyo, Oct. 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063303) titled 'Prospective observational study of eye problems associated with Datopotamab deruxtecan treatment (WJOG21625B)' on Oct. 16.
Study Type:
Observational
Primary Sponsor:
Institute - West Japan Oncology Group
Condition:
Condition - Breast Cancer
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the incidence and severity of Datopotamab deruxtecan related ocular adverse events
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
=18 years at the time of informed consent.
4) No prior treatment with Dato-DXd.
5) Planned initiation of Dat...